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Abstract
Cannabinoids comprise the plant‐derived compounds and their synthetic  derivatives as 
well as endogenously produced lipophilic mediators. Phytocannabinoids are terpenophe‐
nolic secondary metabolites predominantly produced in Cannabis sativa L. The principal 
active constituent is delta‐9‐tetrahydrocannabinol (THC), which binds to endocannabinoid 
receptors to exert its pharmacological activity, including psychoactive effect. The other 
important molecule of current interest is non‐psychotropic cannabidiol (CBD). Since 1970s, 
phytocannabinoids have been known for their palliative effects on some  cancer‐associated 
symptoms such as nausea and vomiting reduction, appetite stimulation and pain relief. 
More recently, these molecules have gained special attention for their role in cancer cell 
proliferation and death. A large body of evidence suggests that cannabinoids affect mul‐
tiple signalling pathways involved in the development of cancer, displaying an anti‐prolif‐
erative, proapoptotic, anti‐angiogenic and anti‐metastatic activity on a wide range of cell 
lines and animal models of cancer. These findings have led to the development of clinical 
studies to investigate potential anti‐cancer activity in humans, but reliable clinical evidence 
for this therapeutic option is still missing.
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1. Introduction
Cannabis sativa L. (Cannabaceae) is one of the first plants cultivated by man and one of the old‐
est plant sources of fibre, food and remedies. It has a long history of medical use in the Middle 
East and Asia, dating back to the sixth century BC. During a period of colonial expansion in the 
early nineteenth century, cannabis found a way to Western Europe as a medicine to alleviate a 
variety of conditions, such as pain, spasms, dysentery, depression, sleep disturbance and loss of 
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 appetite. In the beginning of the twentieth century, due to the availability of substitute drugs, 
absence of quality control and the risk of abuse and intoxication, cannabis medication fell into 
disuse. Moreover, following the UN Single Convention on Narcotic Drugs in 1961, cannabis 
and its products were classified as narcotics. Phytochemical analysis of cannabis in the 1940s 
and 1960s led to the discovery of a unique group of terpenophenolic  secondary metabolites, 
known as cannabinoids, of which  trans‐(−)‐delta‐ 9‐ tetrahydrocannabinol (THC) was shown to 
be the primary active constituent which is responsible for the plant’s psychoactive effect [1–3]. 
Many natural products besides cannabinoids have been isolated from cannabis, including ter‐
penes, flavonoids, steroids and nitrogenous compounds. Up to date, 750 constituents have been 
identified from cannabis, out of which over 100 are classified as cannabinoids [4, 5]. Research 
of the cannabis medical properties has gained worldwide interest after the discovery of two 
types of cannabinoid receptors, which are G‐protein coupled receptors specifically respond‐
ing to endocannabinoids and phytocannabinoids, and related synthetic cannabimimetic com‐
pounds. Therefore, the term cannabinoids now includes not only the plant‐derived compounds 
( phytocannabinoids), but also in laboratory synthesised derivatives (synthetic cannabinoids) 
and a family of endogenously produced compounds (endocannabinoids) [6]. The therapeutic 
properties of cannabis have been much debated from scientific and regulatory points of view 
over the years. The medical use of cannabis is still controversial and strongly limited by unavoid‐
able psychotropic effects. However, solid scientific data indicated the potential of therapeutic 
value of cannabis in controlling some forms of pain, relieving  chemotherapy‐induced nausea 
and vomiting, treating cachexia and anorexia in AIDS patients and combating muscle spasms 
in multiple sclerosis with no evidence that giving cannabis to the patients would increase illicit 
drug use in the general population [7]. Nowadays, many countries legalised cannabis for medical 
purposes. To avoid abuse, numerous centres for cannabis therapy are founded worldwide and 
usually organised as clinics where cannabis can be prescribed in various forms, including dried 
plant material and cannabis extract. So far, only three cannabis‐based medicines have been reg‐
istered for certain indications. In the context of cancer, dronabinol (synthetically generated THC) 
and nabilone (a synthetic THC analogue) can be prescribed to prevent chemotherapy‐induced 
nausea and vomiting. Nabiximols, plant extract enriched in THC and cannabidiol (CBD) at an 
approximate 1:1 ratio, are approved for the treatment of cancer‐associated pain [8]. Apart from 
these palliative effects, recent preclinical studies suggest that various cannabinoids exert anti‐
tumour effects in different experimental cancer models [1]. In this chapter, we will focus on 
phytochemistry and pharmacology of cannabinoids as well as their current and potential roles 
in symptom management and cancer therapy.
2. The cannabis plant
The concept of Cannabis as a monotypic genus containing just a single highly polymorphic spe‐
cies is widely accepted, although there has been a long‐standing debate among  taxonomists 
regarding classification of the existing varieties. Other previously described species,  including 
C. indica Lam. and C. ruderalis Janisch., are now recognised as varieties of C. sativa L. based on 
 morphological, anatomical, phytochemical and genetic studies [9, 10]. C. sativa L. is an annual, 
herbaceous, taprooted and predominantly dioecious plant. Its height (0.2–6 m) and degree of 
branching depend on both genetic and environmental factors. Staminate (male) plants are  usually 
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taller but less robust than pistillate (female) plants. The leaves are petiolate, palmately compound, 
with an odd number (3–13) of coarsely serrate, lanceolate leaflets. The male inflorescence is a lax 
panicle or compound cyme composed of many individual, yellowish green, pedicellate flowers 
containing five pendulous anthers. The pistillate flowers are green, sometimes purple to red, 
sessile, grouped in apical leaf axils or terminals of branches. They form short, congested pseudo‐
spikes among leaf‐like bracts and bracteoles. Each flower has a small green bract enclosing the 
ovary with two long, slender pistils projecting well above the bract. The male plants commence 
flowering slightly before the females. When mature, the sepals on the male flowers are open to 
enable passing air currents to transfer the released pollens to the pistillate flowers. Soon after pol‐
lination, the male plants wither and die in order to secure more space, nutrients and water to the 
females so that they could produce a healthy crop of viable seeds. Following fertilisation, the ovary 
develops into an achene, a fruit containing a single seed with a hard shell [11–13]. The surface of 
aerial plant parts is covered in trichomes. These are either covering (non‐glandular) trichomes 
or glandular trichomes containing a resin (Figure 1). Non‐glandular trichomes are numerous, 
unicellular, rigid and curved hairs, with a slender pointed apex. Cystolithic trichomes found on 
the upper surface of the cannabis leaves are swollen at the base and have calcium carbonate 
crystals (cystoliths), while slender non‐cystolithic trichomes occur mainly on the lower side of 
the leaves, bracts and bracteoles. Three morphologically distinct types of glandular trichomes 
have been identified: (1) a long multi‐cellular stalk and a multi‐cellular head with approximately 
eight radiating club‐shaped cells (capitate‐stalked); (2) sessile with a multi‐cellular head (capitate‐
sessile); (3) a short unicellular stalk and a bi‐cellular, rarely four‐cell, head (bulbous). These are 
mainly associated with the female inflorescences, but they can also be found on the underside of 
the leaves and occasionally on the stems of young plants. Bulbous and capitate‐sessile trichomes 
occur on all parts of vegetative and flowering shoots. In contrast, capitate‐stalked trichomes are 
restricted to flowering regions. The glandular trichomes are secretory structures, where the can‐
nabinoid‐laden resin is produced and stored. Besides cannabinoids, these trichomes produce 
terpenes, which are responsible for the typical plant aroma. The extreme variations in canna‐
binoid contents of the different tissues are due to markedly different distributions of glandular 
trichomes on the surface of the plant [14, 15]. The unfertilised flower heads and flower bracts of 
the female plant are the primary source of cannabinoids (Figure 1).
Figure 1. Cannabis sativa L. – dried pistillate inflorescences and trichomes on their surface. (a) dried pistillate inflorescences 
(50% of the size); (b) non‐cystolithic trichome; (c) cystolithic trichome; (d) capitate‐sessile trichome; (e) simple bulbous 
trichome; (f) capitate‐stalked trichome (400×).
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3. Biosynthesis and structure of phytocannabinoids
Phytocannabinoids represent a group of terpenophenolic compounds predominantly produced 
in the cannabis plant. These secondary metabolites are biosynthesised as prenylated aromatic 
carboxylic acids, and while almost no neutral forms can be found in fresh plants. However, can‐
nabinoid acids may convert to their neutral homologues by spontaneous decarboxylation under 
the influence of light, heat or prolonged storage. The precursors of phytocannabinoids originate 
from two distinct biosynthetic pathways: the polyketide pathway, giving rise to olivetolic acid 
(OA) or divarinic acid (DA), and methylerythritol phosphate pathway, leading to the synthesis 
of geranyl pyrophosphate (GPP). The biogenesis of phytocannabinoids containing n‐pentyl side 
chain starts with the condensation of OA and GPP into cannabigerolic acid (CBGA), catalysed 
by geranyl pyrophosphate—olivetolate geranyl transferase (GOT). The isoprenylation step is 
next followed by activity of three corresponding oxidative cyclases that generate tetrahydro‐
cannabinolic acid (THCA), cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA) from 
CBGA as the key intermediate. The phytocannabinoid acids are non‐enzymatically decarboxyl‐
ated into cannabigerol (CBG), delta‐9‐tetrahydrocannabinol (delta‐9‐THC), cannabidiol (CBD) 
and cannabichromene (CBC) [16, 17]. Figure 2 shows the cannabinoid biosynthetic pathway 
and the structures of the major constituents. The biosynthesis of phytocannabinoids with C3 
side‐chain (propyl cannabinoids) from DA probably follows a similar pathway yielding can‐
nabigerovarinic acid [18].
Over 100 various phytocannabinoids have been found so far, but many of them are pro‐
duced in trace quantities or represent auto‐oxidation artefacts [16, 19]. The structural diver‐
sity of naturally occurring cannabinoids is the result of differences in the nature of their 
isoprenyl residue, resorcinyl core and side chain. Based on the structural variation, Hanuš 
and coworkers [4] have classified phytocannabinoids as follows: cannabigerol, cannabi‐
chromene, cannabidiol, tetrahydrocannabinol, cannabinol, thymyl, cannabielsoin, canna‐
bicyclol and 8,9‐secomenthyl types. The Cannabigerol type compounds are one of the most 
structurally diversified classes of phytocannabinoids. A linear isoprenyl residue is their 
main feature, as exemplified by CBG, which was the first structurally elucidated and also 
the first natural cannabinoid to be synthesised. The isoprenyl residue of CBG is non‐oxy‐
genated, indicating its early biogenetic stage within phytocannabinoids. Other components 
of this type are propyl side‐chain analogues (cannabigerovarin) and monomethyl ether 
derivative. The isoprenyl residue is oxidatively fused to the resorcinyl ring in the canna‐
bichromene type. Cannabichromene (CBC) is the simplest natural cannabinoid to obtain by 
synthesis and the only major phytocannabinoid that shows a bluish fluorescence under UV 
light. CBD, as the main representative of the cannabidiol type compounds, was isolated in 
1940, but the correct structure elucidation was reported more than two decades later. CBD 
and its corresponding acid are the most abundant cannabinoids in the fibre‐type of can‐
nabis (non‐psychotropic). Ten CBD type phytocannabinoids with C1–C5 side‐chains have 
been described. The tetrahydrocannabinol type compounds contain several bis‐reduced forms 
of cannabinol (CBN), differing in location of the remaining double bond, the configuration 
of the chiral centres, or both isomeric options. The most prominent constituent of this sub‐
class is delta‐9‐THC, the main psychoactive ingredient of cannabis plant, isolated in 1942, 
but structurally elucidated only in 1964. Other  representative of this type is delta‐8‐THC, 
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most likely to be generated from delta‐9‐THC or CBD. It is easier to synthesise and more 
thermodynamically stable than delta‐9‐THC. CBN and its derivatives and analogues (can‐
nabinol type) are considered artefacts derived from oxidative aromatisation of the corre‐
sponding THC type compounds. Their concentration in cannabis products depends on age 
and storage condition. CBN is highly stable towards oxidative degradation and so has been 
used as a marker for the identification of narcotic cannabis in archaeological findings. The 
structural hallmark of thymyl type represented by cannabinodiol and cannabifuran is the 
presence of thymyl group obtained by aromatisation of the menthyl moiety of CBD. The 
Cannabielsoin type compounds are the result of the intra‐molecular opening of cannabidiol‐
type epoxides and could be isolated artefacts. Cannabielsoin (CBE) is the major  pyrolytic 
product of CBD and therefore expected to be present in cannabis smoke. Other artefacts 
formed during storage of the plant material in the presence of light are cannabicyclol (CBL) 
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Figure 2. Biosynthesis and degradation of the major phytocannabinoids. OA—olivetolic acid; GPP—geranyl pyrophos‐
phate; GOT—geranyl pyrophosphate—olivetolate geranyl transferase; CBGA—cannabigerolic acid; CBG—cannabigerol; 
CBCAS—cannabichromenic acid synthase; THCAS—tetrahydrocannabinolic acid synthase; CBDAS—cannabidiolic acid 
synthase; CBCA—cannabichromenic acid; THCA—tetrahydrocannabinolic acid; CBDA—cannabidiolic acid; CBC—
cannabicromene; delta‐9‐THC—delta‐9‐tetrahydrocannabinol; CBD—cannabidiol; CBL—cannabicyclol; CBN—cannabinol; 
CBE—cannabielsoin.
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and its derivatives, characterised by a five‐atom ring and C1 bridge instead of a  typical 
six‐membered ring in the cannabinoid structure. 8,9‐Secomenthyl cannabidiols are formed by 
splitting of the endocyclic double bonds of delta‐9‐THC (cannabicoumaronone) and CBD 
(cannabimovone) [4, 19, 20].
4. Phytochemical characterisation of cannabinoids
Various scientific attempts have been made to classify Cannabis taxa based on their canna‐
binoid composition, which is under strong environmental influences and also depends on 
plant sex and maturity. The most important classification of cannabis types in forensics and 
legislation is that into drug type (marijuana) and fibre type (hemp). A high amount of psy‐
choactive THC characterises the drug type, while particularly low content defines the fibre 
type [21, 22]. Nowadays, cannabis is divided mainly into three chemotypes (i.e. chemical 
phenotypes) on the basis of the content ratio of the two major cannabinoids, THC and CBD, 
in dried inflorescence: (1) THC > 0.3% and CBD < 0.5% (THC predominant); (2) THC ≥ 0.3% 
and CBD > 0.5% (intermediate); (3) THC < 0.3% and CBD > 0.5% (CBD predominant). Two 
rare chemotypes with prevalence of CBG and cannabinoid‐free, respectively, have also been 
found [23, 24]. Apart from these chemotypes, de Meijer [25] has additionally described CBC, 
delta‐9‐tetrahydrocannabivarin (THCV) and other propyl cannabinoid‐rich chemotypes. A 
large variation of cannabis strains have been developed during a long period of breeding 
and selection. Over 700 different cultivars of cannabis have been catalogued and many more 
varieties are thought to exist [26]. With the increasing use of cannabis for medical purposes, 
the need for a clear chemotaxonomic distinction between varieties has become even more 
important. Phytocannabinoids were chosen as chemotype markers as they are considered to 
be the main pharmacologically active constituents in cannabis [27].
Because of the complex chemistry of cannabis, advanced separation techniques, such as 
gas chromatography (GC) or high performance liquid chromatography (HPLC), often 
coupled with mass spectrometry detection (MS), are necessary for the determination of 
the typical phytochemical profiles of cannabis constituents [28, 29]. Thin layer chroma‐
tography (TLC) is suitable only for identification of cannabis plant material, detection of 
its principal cannabinoids and distinguishing between main chemotypes. The separation 
of phytocannabinoids is mainly achieved by using silica gel as stationary phase, reversed 
phase for the non‐polar system and normal phase for the polar system. Two different 
reagents for the visualisation of cannabinoids, fast blue and vanillin‐sulphuric acid, can be 
used [11, 30, 31]. Figure 3 shows  high performance thin layer chromatography (HPTLC) 
chromatogram of cannabis ethanolic extracts, representing THC and CBD predominant 
types, respectively.
Gas chromatography, commonly coupled to flame ionisation detection (FID) or MS, provides 
data only on neutral cannabinoids. Due to the high temperature of the injection port, the rapid 
decarboxylation of the acidic cannabinoids to the neutral forms occurs, thus the real cannabi‐
noid profile of the plant material does not correspond to the results obtained. Derivatisation of 
phytocannabinoid acids to their trimethylsilyl esters before injection is one approach that can 
allow the separation and detection of the acidic and neutral forms. Identification of the phy‐
tocannabinoids is most readily performed by GC‐MS, method of choice for creating cannabis 
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profiles and metabolic fingerprints [12, 28, 32]. GC‐FID is suitable for routine identification and 
quantification of the major phytocannabinoids as illustrated in Figure 4, representing THC and 
CBD predominant types, respectively.
Figure 3. HPTLC chromatogram of phytocannabinoids in the concentrated ethanolic extracts of cannabis inflorescence. 
Cs1—THC predominant type of Cannabis sativa extract; Cs2—CBD predominant type of Cannabis sativa extract; stationary 
phase: HPTLC silica gel C
18
 F254; mobile phase: methanol‐water with 0.1% glacial acetic acid 75:25 (V/V); detection: Fast 
blue reagent; R
f
 (THC) = 0.25; R
f
 (CBD) = 0.38.
Figure 4. GC‐FID chromatograms of two concentrated ethanolic extracts of cannabis inflorescence. (a) THC predominant 
type of cannabis extract (THC/CBD = 87;2). (b) CBD predominant type of cannabis extract (THC/CBD = 0.08). Agilent 
7890A gas chromatograph equipped with FID; HP‐5MS column (15 m x 0.25 mm i.d., 0.25 µm film thickness); carrier 
gas: helium at a constant flow rate of 2.0 mL/minute; temperature program: initial temperature 200°C for 2 minutes, 
increased by 10°C/minute to final temperature 240°C and held for further 2 minutes; detector temperature 300°C; injector 
temperature 280°C with split ratio of 20:1; injection volume 1.5 µL; i.s. – tribenzylamine (TBA).
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Both acidic and neutral forms of phytocannabinoids can be directly analysed by means of 
HPLC without any derivatisation step. In contrast to GC, no decomposition occurs dur‐
ing HPLC analysis, which is the main advantage for obtaining the complete cannabinoid 
profiles. Analytical methods based on reversed‐phase chromatography with gradient elu‐
tion are commonly used. Detection of phytocannabinoids is usually performed by UV and 
diode array detectors (DAD), but high sensitivity can best be achieved through the use 
of thermospray MS. Apart from several HPLC methods, ultra performance liquid chro‐
matography (UPLC) method has also been validated for the analysis of a wide range of 
phytocannabinoids in plant material [13, 29]. Moreover, a novel method of ultra‐high per‐
formance supercritical fluid chromatography (UHPSFC) coupled with DAD/MS for the 
separation and discrimination of cannabinoids in complex matrices has been developed 
and validated [33]. Giese et al. [5] highlighted that typical concentration ranges for the can‐
nabinoids vary from 0.1 to 40% of inflorescence dry weight. These data show how extreme 
the variations of phytocannabinoids between plant specimens can get, indicating that the 
cannabis for medical use should always be thoroughly profiled. Therefore, the previously 
mentioned analyses are of interest given the probability that both the therapeutic and 
adverse effects of cannabis may be dictated by the concentrations and interactions of cer‐
tain phytocannabinoids.
5. The endocannabinoid system
The endocannabinoid system (ECS) consists of endogenous cannabinoids, their receptors 
and the enzymes responsible for their biosynthesis, transport and degradation. The endocan‐
nabinoids are lipophilic mediators, which include amides, esters and ethers of long‐chain 
polyunsaturated fatty acids, mostly arachidonic acid. The first two identified and most 
studied endocannabinoids are N‐arachidonylethanolamide called anandamide (AEA) and 
2‐ arachidonoylglycerol (2‐AG) (Figure 5). AEA and 2‐AG are not pre‐synthesised and stored 
in vesicles like classical neurotransmitters, but rather released from the cells immediately after 
biosynthesis. They are synthesised via enzymatic pathways from phospholipid  precursors 
in the plasma membrane of post‐synaptic cells on demand upon relevant physiological or 
pathological stimuli. After release, acting as retrograde messengers, AEA and 2‐AG travel 
backwards to stimulate receptors on the pre‐synaptic membrane. The main intermediate in 
the synthesis of AEA is N‐acyl‐phosphatidylethanolamine (NArPE), transformed into anan‐
damide by several possible pathways among which the most investigated is the direct conver‐
sion catalysed by an enzyme of phospholipase D family. 2‐AG is produced primarily by the 
hydrolysis of diacylglycerols (DAGs) via DAG lipases α and β. The endocannabinoids act on 
their receptors only locally, possibly because of their high lipophilicity, and are immediately 
inactivated under physiological conditions. The suggested mechanisms of endocannabinoid 
transport across the plasma membrane (facilitated transport, passive diffusion and/or endocy‐
tosis) are still not fully elucidated. After their cellular re‐uptake, AEA is rapidly degraded by 
the enzyme fatty acid amide hydrolase (FAAH) while 2‐AG is hydrolysed by monoacylglyc‐
erol lipase (MAGL) forming arachidonate and ethanolamine or glycerol, respectively [34, 35]. 
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Apart from hydrolytic degradation, endocannabinoids may also be oxidised by cyclooxygen‐
ase‐2, lipoxygenases and cytochrome P450 [36].
The cannabinoids exert their effects by binding to specific receptors, among which the most 
important are cannabinoid receptors CB1 and CB2 encoded by different genes and exhibit‐
ing 44% homology in their primary structure. They belong to the large rhodopsin family of 
G‐protein‐coupled receptors (GPCRs) with seven transmembrane domains connected by three 
extracellular and three intra‐cellular loops, an extracellular N‐terminal tail and an intra‐cel‐
lular C‐terminal tail. There is increasing evidence supporting the existence of  additional tar‐
gets for cannabinoids like transient receptor potential (TRP) ligand‐gated cation channels 
(vanilloid type 1, TRPV1, melastatin type 8, TRPM8 and ankyrin type 1, TRPA1), certain 
orphan GPCRs (GPR55, GPR119 and GPR18), 5‐hydroxytryptamine receptor subtype 1A 
(5‐HT
1A
) and peroxisome proliferator‐activated receptors (PPARs). The functions of canna‐
binoid receptors can be modulated by endo‐, phyto‐ or synthetic‐cannabinoids which target 
the orthosteric or allosteric binding sites on the receptors. The cannabinoid receptors modu‐
late adenylyl cyclase (AC) activity depending on its isoform expressed in the cells and, conse‐
quently, alter the cellular production of second messenger cyclic adenosine monophosphate 
(cAMP). The activation of CB1 and CB2 receptors mainly causes inhibition of AC and the 
subsequent reduction of intra‐cellular cAMP levels leads to the inactivation of the protein 
kinase A (PKA) phosphorylation pathway. Studies have shown that cannabinoid receptors 
can also be coupled to other types of intra‐cellular signals, such as the protein kinase B, 
phosphoinositide 3‐kinase and phospholipase C pathway. Also, activation of CB1 and CB2 
receptors leads to the downstream activation of mitogen‐activated protein kinase (MAPK), 
p44/42, p38 and c‐JUN amino terminal kinase as signalling pathways to regulate nuclear 
 transcription factors. Unlike the activation of CB2 receptor, which generally has no effect on 
ion channels, CB1 receptors inhibit calcium channels and activate potassium channels. The 
cannabinoid receptors are widely distributed in the human body. CB1 receptors are localised 
predominantly in the CNS and mainly expressed in areas that are involved in the control of 
motor coordination and movement, memory, learning, emotions, sensory perception and 
autonomic and endocrine functions. In addition, CB1 receptors are present to a lesser extent 
in some organs and peripheral tissues, including endocrine glands, leukocytes, adipocytes, 
spleen, liver, heart and part of the reproductive, urinary and gastrointestinal systems. By 
contrast, the CB2 receptor was initially described as present in the immune system, but more 
recently it has also been shown to be expressed in additional cell types [37–40]. Since ele‐
vated expression of CB1 and CB2 receptors and higher levels of endocannabinoids have been 
found in many types of cancer, compared to normal tissues, the ECS has been recognised 
as attractive potential target for cancer therapy. The growing evidence over the past decade 
suggests that cannabinoids affect multiple signalling pathways involved in the development 
Figure 5. The structures of main endocannabinoids anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG).
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of cancer, displaying an anti‐proliferative, proapoptotic, anti‐angiogenic and anti‐metastatic 
activity on a wide range of cell lines and animal models of cancer [41].
6. Preclinical evidence on cannabinoids as anti‐cancer agents
Despite remarkable advances in understanding and treating cancer, finding new, more effec‐
tive pharmacotherapeutics still remains a key challenge for scientists worldwide. The first 
study suggesting that plant‐derived cannabinoids might be potential anti‐cancer agents, 
demonstrating their ability to inhibit tumour growth in vitro and in vivo and to increase the 
survival of lung cancer‐bearing animals, was published more than 40 years ago [42]. Later 
discoveries of the ECS in the human body, combined with the development of numerous 
preclinical testing models, have paved the way for a renaissance in the study of anti‐cancer 
properties of cannabinoids in the last two decades. A large body of in vitro data has been accu‐
mulated demonstrating that cannabinoids affect a wide spectrum of tumour cells, including 
gliomas, neuroblastomas, lymphomas, hepatocarcinoma as well as thyroid, skin, prostate, 
pancreatic, breast, cervical, colon, gastric, lung and some other cancers [6, 41, 43]. Several 
plant‐derived (THC and CBD), synthetic (e.g. JWH‐133, WIN‐55,212‐2 and KM‐233) and 
endogenous cannabinoids (AEA and 2‐AG) were found to be potent inhibitors of both cancer 
growth and spreading due to their ability of modulating various cell‐signalling pathways 
[6, 37, 43, 44]. Their anti‐neoplastic action mainly relies on the activation of cannabinoid CB1 
and/or CB2 receptors, although some other non‐CB1/CB2 receptors, like TRPV1 and PPARs, 
as well as mechanisms unrelated to receptor stimulation may also be involved [43, 45, 46]. 
Cannabinoids might stop the uncontrolled growth of cancer cells by several different mecha‐
nisms, including inhibition of cell‐cycle progression, inhibition of cell proliferation as well as 
induction of autophagy and apoptosis [41, 43, 44]. Due to their modulatory actions on various 
cell cycle regulatory molecules, like cyclin A and cyclin dependent kinase (CDK) 2, cannabi‐
noids have been shown to cause arrest of cell cycle progression in different phases (e.g. G0/G1, 
G2/M), leading to growth inhibition and/or apoptotic death of cancer cells [43]. The anti‐pro‐
liferative activity is based on their ability to inhibit proliferative and oncogenic pathways in 
cancer cells, such as adenylyl cyclase and cyclic adenosine monophosphate/protein kinase A 
(cAMP/PKA) pathway leading to the activation of mitogen‐activated protein kinase (MAPK) 
pathway as well as cell cycle blockade with induction of the CDK inhibitor (CDKI) p27Kip1 
and p21waf, decrease in epidermal growth factor (EGF) receptor (EGFR) expression and/or 
attenuation of EGFR tyrosine kinase activity, decrease in the activity and/or expression of 
nerve growth factor (NGF), prolactin, or vascular endothelial growth factor (VEGF) tyrosine 
kinase receptors. The MAPK signalling cascades, consisting of the extracellular signal‐regu‐
lated kinase (ERK1/2), c‐Jun N‐terminal kinase (JNK) and p38 MAPK, as well as phosphati‐
dylinositol 3 kinase (PI3K)‐Akt pathways seems to have a prominent role in the control of 
tumour cell fate by cannabinoids [43, 45]. Cancer cell death‐inducing activity of cannabinoids 
relies greatly on the apoptosis and, among several molecular mechanisms, the stimulation of 
endoplasmic reticulum (ER) stress and subsequent autophagy has been recently suggested 
as the most common one. Cannabinoids can induce accumulation of de novo–synthesised 
ceramide and thereby activate an ER stress‐related response through up‐regulation of the 
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stress‐regulated protein p8 and several of its downstream targets, like activating transcription 
factor 4 (ATF4), C/EBP homologous protein (CHOP) and pseudokinase tribbles‐homologue 
3 (TRIB3), leading to the inhibition of the AKT–mammalian target of rapamycin complex 
1 (mTORC1) signalling, and autophagy‐mediated apoptosis. Cannabinoid‐evoked and ER 
stress‐dependent activation of calcium/calmodulin‐dependent protein kinase β (CaCMKKβ) 
and AMP‐activated protein kinase (AMPK) lead, together with the p8/TRIB3 pathway, to 
autophagy and apoptosis [1, 46]. Tumour angiogenesis represents additional important tar‐
get for cancer therapy affected by cannabinoids. They can directly inhibit vascular endothelial 
cell migration and survival or act indirectly by modulating the expression of pro‐angiogenic 
factors, like VEGF, matrix metalloproteinase‐2 (MMP‐2) or anti‐angiogenic factors like tis‐
sue inhibitor of matrix metalloproteinase 1 (TIMP‐1) as well as their receptors in tumours 
[41, 44]. Besides influencing the growth of different cancer cells, cannabinoids may exert their 
anti‐cancer effects by inhibiting all the steps of tumour progression. The inhibitory effect on 
migration, adhesion and invasion through CB receptors is related to the blocking of key path‐
ways such as EGF‐EGFR, RhoA‐RhoA kinase (ROCK), focal adhesion kinase (FAK)‐Src and of 
MMPs and TIMP‐1, which are fundamental for the invasiveness and spread of tumours [41, 
43, 44]. Non‐CB receptors mediated anti‐metastasic effects may rely on the down‐regulation 
of the helix‐loop‐helix (bHLH) transcription factor inhibitor of DNA binding 1 (ID1) [46]. 
Tables 1 and 2 summarise preclinical evidence collected during the last decade about the role 
of two most‐investigated phytocannabinoids, THC and CBD, in different type of cancers and 
their associated cell signalling pathways.
Recent in vivo studies demonstrated that cannabinoids of plant, synthetic and endogenous 
origin are able to decrease tumour growth and metastasis of different experimental can‐
cers [47]. Preclinical assessments have mainly been conducted using human tumour engraft 
models, where human cancer cells were subcutaneously injected (ectopic model) or trans‐
planted into the same origin site of the tumour (orthotropic model) in immunodeficient 
mice. The  syngeneic (allograft) models, established by transplantation of mice cancer cells 
in immunocompetence animals, as well as carcinogen‐induced spontaneous tumour models 
and genetically engineered mouse models (GEMM) have also been used, but rarely [47, 48]. 
An overview of last decades’ discoveries revealed the effectiveness of THC against experi‐
mental glioma, liver, pancreatic, breast and lung cancers (Table 1) while CBD was found to be 
effective against glioma and neuroblastoma, melanoma, colon, breast, prostate and lung can‐
cers (Table 2). Among other phytocannabinoids, CBG could be considered as a candidate for 
colon cancer prevention and treatment [49]. Beside these findings, the potential clinical inter‐
est of cannabinoids is additionally strongly suggested by their selectivity for tumour cells 
(and even ability to protect the non‐transformed cells) as well as by their good tolerance in 
animal studies and the absence of normal tissue toxicities that are still the major limitations of 
most  conventional  chemotherapeutics [45]. However, several studies reported that THC and 
some other cannabinoids can inhibit apoptosis in the transformed‐cell lines, exhibit proangio‐
genic effect and stimulate cancer cell proliferation or show a biphasic effect in cancer cells by 
increasing their proliferation at lower concentrations and decreasing at higher  concentrations 
[37, 41]. The ability to promote the tumours growth was found in two experimental animal 
model cancers and attributed to their suppression of anti‐tumour immune response [37]. 
Despite the few mentioned conflicting data, the majority of recent preclinical studies provide 
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the supporting evidence on cannabinoids as promising anti‐cancer agents, thus encouraging 
further clinical investigations.
Considering the possibilities for therapeutic use of cannabinoids in cancer, their combina‐
tion with traditional chemotherapy or radiotherapy seems to be an interesting option. The 
possible advantages of combination therapy may be a synergistic effect evident as improved 
efficiency, lowered doses and consequently attenuated toxic side effect or reduced drug 
 resistance. Accordingly, γ‐irradiation was found to enhance CBD‐induced apoptotic death 
in cultured leukaemia cells [50]. Synergism of plant‐derived cannabinoids and radiation was 
confirmed in vivo, where the simultaneous treatment with THC and CBD enhanced the  cancer‐
killing effects of the radiation in murine glioma model [51]. Preclinical evidence also supports 
the combination of phytocannabinoids and chemotherapy drug  temozolomide (TMZ), com‐
monly used in patients with glioblastoma. Torres et al. [52] proved that  co‐ administration 
of TMZ with THC reduces the growth of glioma xenograft to a much higher extent than 
the treatment with the individual agents, observing effect in the TMZ‐resistant tumours 
also. Interestingly, combined treatment with TMZ and submaximal doses of THC and CBD 
(approximate 1:1 ratio) produced similar anti‐tumoural effect in both TMZ‐sensitive and 
TMZ‐resistant tumours. Usage of main cannabis constituents together may be therapeutically 
very attractive, since CBD has the ability to potentiate anti‐cancer properties of THC and, as a 
non‐psychotropic cannabinoid, can mitigate adverse psychoactive effects of THC that limit its 
clinical use [46, 52]. Recent data also revealed that CBD‐enriched cannabis extract can signifi‐
cantly enhance the efficacy of bicalutamide or docetaxel, two standard drugs used in the treat‐
ment of prostate cancer, and taken together even prolong the survival of treated animals [53]. 
Overall, recent findings provide promising evidence on the benefits of cannabinoid‐based 
combinational therapy in cancer, and suggest novel therapeutic opportunities that need to be 
clinically proven in future.
Cancer type Experimental model Findings [reference]
Brain
(Glioma)
in vitro
U251MG, U87MG
C6.9, U87MG
C6.9, U87MG
U87MG
in vivo
C6.9 xenograft
U87MG xenograft
Inhibited cell cycle progression (G0/1 arrest) by down‐
regulation of E2F transcription factor 1 and cyclin A [54]
Inhibition of migration by inhibition of TIMP‐1 
expression via ceramide and stress protein p8 [55]
Inhibition of invasion by down‐regulating MMP‐2 via 
ceramide and p8 [56]
Induced autophagy‐mediated cell death through ER 
stress–evoked stimulation of ceramide synthesis de 
novo, eIF2α phosphorylation and up‐regulation of p8/
TRIB3 pathway leading to inhibition of Akt/mTORC1 
pathway; autophagy leads to apoptosis [57]
Decreased tumour growth and tumoural TIMP‐1 
expression [55]
Decreased tumour grow and tumoural MMP‐2 
expression [56]
Decreased tumour growth and activated autophagic 
mediated cell death pathway (↑TRIB3, ↑LC3‐II, ↑caspase 
3, ↓rpS6) [57]
Natural Products and Cancer Drug Discovery122
Cancer type Experimental model Findings [reference]
Lung in vitro
A549, SW‐1573
in vivo
A549 xenograft
LL2 allograft
Inhibited proliferation, migration and invasion of 
tumour cells by inhibition of EGFR‐mediated activation 
of MAPKs (ERK1/2, JNK1/2) [58]
Reduced tumour growth and metastasis through 
inhibition of proliferation (↓Ki67), vascularisation 
(↓CD31) and decreased phosphorylation of FAK, 
ERK1/2 and Akt [58]
No significant effect on tumour growth [59]
Liver in vitro
HepG2, HuH‐7
HepG2
in vivo
HepG2 xenograft
HuH‐7 xenograft
HepG2 orthotopic
HepG2 xenograft
Induced cancer cell death through autophagy 
stimulation
via CB2 receptors by (i) inhibition of the Akt/mTORC1 
axis via ER stress with TRIB3 up‐regulation and (ii) 
stimulation of AMPK via CaMKKβ; autophagy leads to 
apoptosis [60]
Anti‐proliferative action modulated by up‐regulation of 
PPARγ‐dependent pathways through TRIB3 [61]
Reduced tumour growth relies on decreased mTORC1 
activation, enhanced AMPK phosphorylation and 
increased autophagy and apoptosis [60]
Decreased hepatomegaly and ascites, ↓α‐fetoprotein, in 
tumour ↑pAMPK, ↓pAkt, ↓pS6, ↓procaspase‐3 [60]
Reduced tumour growth via PPARγ activation [61]
Pancreas in vitro
MiaPaCa2, Panc1
in vivo
MiaPaCa2 xenograft
Induced cancer cell death by apoptosis via activation of 
the p8‐ATF‐4‐TRIB3 pathway (↑caspase‐3, ↑ceramide) 
[62]
Reduced tumour growth [62]
Breast in vitro
EVSA‐T, HMEC
in vivo
MMTV‐neu
N202.1 xenograft
Reduced cancer cell proliferation through apoptosis 
and cell cycle blockade (G2‐M arrest) by CDK1 down‐
regulation [63]
Reduced tumour growth, tumour number and 
metastases by cell proliferation inhibition (↓Ki67), 
apoptosis (↑caspase 3), decreased angiogenesis and 
↓MMP2 [64]
Decreased tumour growth via Akt inhibition [64]
Skin in vitro
CHL‐1, A375,
SK‐MEL‐28
in vivo
CHL‐1 xenograft
HCmel12 xenograft
Induced cancer cell death by activating non‐canonical 
autophagy‐mediated apoptosis dependent on Atg7 
but not Beclin‐1 or Ambra1 [65]
Inhibited tumour growth via autophagy and apoptosis
(↓Ki67, ↑TUNEL, ↑LC3) [65]
Reduced tumour growth in CB receptor‐dependent 
manner and decreased inflammatory immune cell 
infiltrates in the tumour microenvironment [66]
Table 1. Effects of THC on different types of cancer.
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Abbreviations are listed in Table 2.
Cancer type Experimental model Findings [reference]
Brain In vitro
U87
in vivo
U87 xenograft
U251 orthotopic
xenograft
3832, 387 orthotopic
xenograft
SK‐N‐SH xenograft
Induced apoptosis of cancer cells through 
caspase
activation (↑caspase‐8, ‐9 and ‐3) and oxidative 
stress (↑ROS, ↓GSH, ↑GPx, ↑GRed) [67]
Reduced tumour growth through inhibition 
of 5‐LOX (↓LTB4) and ECS—activation of FAAH 
(↓AEA) [68]
Reduced tumour progression and cancer cell 
invasion through down‐regulation of Id‐1 
expression [69]
Initial inhibition of tumour growth (↓Ki67, 
↓pAkt, (↑caspase‐3) followed by tumour 
resistance [70]
Suppressed neuroblastoma tumour growth via 
apoptosis induction (↑caspase‐3) [71]
Lung In vitro
A549, H460
in vivo
A549 xenograft
Anti‐invasive and anti‐metastatic action via 
up‐regulation of ICAM‐1 which leads to 
enhanced cancer cell adhesion to LAK cells 
and subsequent enhance of LAK cell‐mediated 
cancer cell lysis [72]
Decreased tumour growth and inhibited tumour 
cell invasion via down‐regulation of PAI‐1 [73]
Decreased tumour metastasis [74]
Inhibited cancer cell invasion and metastasis 
by stimulation of TIMP‐1 via up‐regulation of 
ICAM‐1 [75]
Decreased tumour growth via apoptosis caused 
by up‐regulation of COX‐2 and PPAR‐γ [76]
Colon In vivo
Azoxymethane‐induced cancer Reduced preneoplastic lesions, number of 
polyps and tumours through apoptosis by 
inhibition of the PI3K‐Akt pathway (↓pAkt, 
↑caspase 3) [77]
Prostate In vitro
LNCaP, DU‐145
LNCaP
in vivo
LNCaP xenograft
Induced cell death through apoptotic pathways 
(↑caspase 3, ↑PUMA, ↑CHOP, ↑intra‐cellular 
Ca2+, down‐regulation of AR, p53 activation, 
↑ROS) [53]
Induced phosphatase‐dependent apoptosis in 
cancer cells via CB1/CB2 [78]
Decreased tumour growth [53]
Natural Products and Cancer Drug Discovery124
Cancer type Experimental model Findings [reference]
Breast In vitro
MCF‐7, KiMol, C6, MDA‐MB‐231
MDA‐MB‐231, 4T1
MDA‐MB‐231
SUM159, 4T1.2
In vivo
MDA‐MB xenograft
4T1 orthotopic
4T1 allograft
4T1.2 orthotopic MVT‐1 orthotopic
Inhibited cancer cell proliferation through 
proapoptotic effect and by cell cycle blockade at 
G1/S phase, acting directly via CB2 and TRPV1 
receptors and indirectly via elevation of intra‐
cellular Ca2+ and ROS [79]
Anti‐proliferative and anti‐invasive effect by up‐
regulation of ERK and ROS pathways leading to 
down‐regulation of Id‐1 protein expression [80]
Induced cancer cell death by both apoptosis 
(↑PARP) and autophagy (↑LC3‐II) through 
induction of ER stress and inhibition of Akt/
mTOR/4EBP1 signalling independently of 
receptor activation; important role of ROS and 
Beclin‐1 [81] Inhibited tumour cell proliferation, 
migration and invasion through EGF/EGFR 
pathway inhibiting EGF‐induced activation 
of EGFR, ERK, Akt and NF‐kB signalling and 
actin stress fibre formation and focal adhesion 
formation; Anti‐metastatic effect also by 
decreasing secretion of MMP‐2 and MMP‐9 as 
well as chemokines CCL3, GM‐CSF, MIP‐2 [82]
Decreased tumour growth and lung metastasis 
[79]
Reduced tumour growth and metastasis. Anti‐
metastatic effect by down‐regulation of tumoural 
Id1 expression [80, 83]
Inhibited tumour growth and lung metastasis 
due to anti‐proliferative (↓Ki67) and angiogenic 
(↓CD31) effects and inhibition of EGFR, Akt and 
ERK activation [82]
AEA—anandamide; Akt—serine/threonine protein kinase; AMPK—adenosine monophosphate‐activated protein kinase; 
AR—androgen receptor; ATF‐4—activating transcription factor 4; Atg7—autophagy‐related protein 7; CaMKKβ—calcium/
calmodulin‐dependent protein kinase β; CCL3—chemokine (C‐C motif) ligand 3; CD31—cluster of differentiation 31, 
syn. platelet endothelial cell adhesion molecule (PECAM‐1); CDK1—Cyclin‐dependent kinase 1; CHOP—transcription 
factor CAAT/enhancer binding homologous protein; COX‐2—cyclooxygenase‐2; 4EBP1—eukaryotic translation initiation 
factor 4E binding protein 1; ECS—endocannabinoid system; EGF—epidermal growth factor; EGFR—epidermal growth 
factor receptor; eIF2α—α subunit of eukaryotic initiation factor 2; ER—endoplasmic reticulum; ERK—extracellular signal‐
regulated kinase; FAAH—fatty acid amide hydrolase; FAK—focal adhesion kinase; GM‐CSF—granulocyte‐macrophage 
colony‐stimulating factor; GPx—glutathione peroxidase; GRed—glutathione reductase; GSH—glutathione; ICAM‐1—
intercellular adhesion molecule 1; Id‐1—helix‐loop‐helix protein inhibitor of DNA binding‐1; JNK1/2—c‐Jun N‐terminal 
protein kinases 1 and 2; Ki67—biomarker of cancer cells proliferation LAK cells ‐ lymphokine‐activated killer cells; LC3—
microtubule‐associated protein 1 light chain 3; 5‐LOX—arachidonate 5‐lipoxygenase; LTB4—leukotriene B4; MAPK—
mitogen‐activated protein kinase; MIP‐2—macrophage inflammatory protein 2; MMP—matrix metalloproteinase; 
mTOR—mechanistic target of rapamycin; mTORC1—mammalian target of rapamycin complex 1; NF‐kB—nuclear 
factor‐kappa B; p53—tumour protein 53; p8—stress‐regulated protein; PAI‐1—plasminogen activator inhibitor‐1; pAkt—
phosphorylated Akt; pAMPK—phosphorylated adenosine monophosphate‐activated protein kinase; PARP—poly (ADP‐
ribose) polymerase; PI3K—phosphoinositide 3‐kinase; PPARγ—peroxisome proliferator‐activated receptor γ; pS6—
phosphorylated‐ribosomal protein S6; PUMA—p53 up‐regulated modulator or apoptosis; ROS—reactive oxygen species; 
rpS6—ribosomal protein S6; TIMP‐1—tissue inhibitor of matrix metalloproteinase 1; TRIB3‐—tribbles pseudokinase 3; 
TUNEL—terminal deoxynucleotidyl transferase dUTP nick end labelling.
Table 2. Effects of CBD on different types of cancer.
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7. Clinical studies of cannabinoids in cancer care
7.1. Clinical anti‐cancer studies
The promising preclinical data have encouraged the development of clinical studies aimed at 
investigating the potential therapeutic value of cannabinoids as anti‐cancer agents. The only 
clinical study published up to date was a pilot phase I trial in which nine patients with  recurrent 
glioblastoma multiforme (GBM) that have previously failed standard therapy  underwent 
intracranial THC administration. The study showed that THC delivery was safe without 
evident psychoactive effects and that THC neither facilitates tumour growth nor decreases 
patients’ survival. Additionally, THC inhibited tumour‐cell proliferation and induced apop‐
tosis in samples obtained from two patients before and after treatment. However, evalua‐
tion of patients’ survival requires a larger study with a different design and preferably oral 
or oromucosal application [46, 84]. According to the register of clinical trials [85], there are 
several on‐going clinical trials evaluating anti‐cancer activity of cannabinoids. Two phase 
I/II clinical studies in recurrent GBM patients are being conducted to assess the safety and 
effectiveness of the administration of an oromucosal spray containing cannabis extract (2.7 
mg THC and 2.5 mg CBD in 100 µL) in combination with dose‐intense TMZ (NCT01812603 
and NCT01812616). These studies have passed their completion date, but the status has not 
yet been verified. Evaluation of pure CBD as a single‐agent for solid tumour (NCT02255292) 
started in 2014 as a phase II clinical trial and still did not reveal any results. Dexanabinol, a 
synthetic cannabinoid, is currently undergoing phase I trial for the treatment of advanced 
solid tumours (NCT01489826). This non‐psychotropic cannabinoid was applied in different 
doses with the intention to determine the maximum safe dose, to understand interactions 
between the body and the drug and to measure any reduction in size of patients’ tumour. 
Data on tumour response and the number of adverse events have not yet been reported.
7.2. Studies on chemotherapy‐induced nausea and vomiting
In contrast to rare clinical anti‐cancer studies, clinical trials evaluating efficacy of  cannabinoids 
in cancer symptom management have a long history. The 1970s and 1980s mark a period of 
intensive clinical trials dealing with chemotherapy‐induced nausea and vomiting (CINV), 
but the interest in these investigations is not decreasing due to the influence of CINV on 
patients’ life quality and compliance with future treatment [86, 87]. Modern anti‐emetic 
treatment includes corticosteroids, serotonin receptor antagonists (5‐HT
3
) and neurokinin 
(NK
1
)  receptor antagonists, while cannabinoids (dronabinol and nabilone) are prescribed 
to the patients who have failed to respond to conventional anti‐emetic therapy [88, 89]. 
Majority of clinical studies have compared efficacy of cannabinoids to dopamine recep‐
tor antagonist and neuroleptics [87], yet some recent studies have been focusing on newer 
generation agents such as 5‐HT
3
 and NK
1
 receptor antagonists. Meiri and coworkers [90] 
have design randomised, double‐blind, placebo‐controlled, parallel group, five‐day study 
for evaluating dronabinol alone and in combination with ondansetron, a 5‐HT
3
 receptor 
antagonist. They recruited 61 patients with delayed CINV, which is defined as nausea and 
vomiting occurring more than 24 hours after chemotherapy and lasting up to one week. 
Obtained results indicated that dronabinol or ondansetron was similarly effective and well 
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tolerated, but combination of these two drugs was not more effective than either drug alone. 
Duran and coworkers [91] conducted a pilot, double‐blind, parallel, placebo‐controlled 
phase II clinical trial with standardised oromucosal cannabis extract containing a mixture 
of THC and CBD (2.7 mg THC and 2.5 mg CBD per spray) in patients with CINV. To be 
recruited in the study, patients had to have moderately emetogenic cancer therapy caused 
CINV  lasting more than 24 hours despite standard anti‐emetic therapy. During five days 
patients were allowed to add up to eight sprays per day along with their standard therapy. 
Combination of cannabis extract with standard anti‐emetic therapy was well tolerated and 
provided better protection against delayed CINV. The benefits of cannabinoids in CINV are 
undoubtedly confirmed in numerous clinical studies, but there is lack of studies dealing 
with cannabis plant [92]. First scientific article about use of smoked cannabis reported it as 
a rescue drug in case of vomiting episodes [93]. In 2001, Musty and Rossi [94] published the 
review about effects of smoked cannabis and oral THC based on previously unpublished 
USA clinical trials with cannabis and/or THC. The investigation included 748 patients who 
smoked cannabis prior to and/or after cancer chemotherapy and 345 patients who used the 
oral THC capsules. Patients who smoked cannabis experienced 70–100% relief from nausea 
and vomiting, while those on THC capsules reported 76–88% relief. Although it is clear 
that cannabinoids can serve as anti‐emetic agents in cancer therapy, clinical studies on their 
effectiveness on nausea and vomiting in advanced cancer and metastasis are needed since 
there are case‐reports in which cannabinoids showed potential therapeutic use for these 
indications [95].
7.3. Studies on cancer‐related pain
In the last decades, available clinical data on benefits of cannabinoids in chronic pain were 
scarce; however, currently there are many clinical studies, which include various cannabinoid 
preparations and test different chronic pain conditions [96]. Animal studies in a variety of noci‐
ceptive assays have confirmed that activation of CB1 receptors by exogenously applied agonists 
can reduce pain sensitivity, while activation of CB2 receptors may promote analgesia without 
psychoactive side effects usual for CB1 agonist [97]. Patients who are suffering from chronic 
cancer‐related pain usually are put on high doses of opiates, which alter their state of con‐
sciousness. It has been reported that cancer patients down‐sized opioid dose after adding can‐
nabis in their pain regimen and when selecting cannabis extract, THC‐rich cannabis extract was 
the first choice, though many patients experienced pain relief after using CBD‐rich type  [92]. In 
multi‐centre, double‐blind, randomised, placebo‐controlled, parallel‐group, two‐week study, 
THC:CBD extract and THC extract were evaluated in patients with intractable cancer‐related 
pain. Study included 177 patients with inadequate analgesia despite opioid dosing. During 
first week patients self‐titrated dose up to maximum of 48 actuations (each 100 µL containing 
2.7 mg THC and 2.5 mg CBD or just 2.7 mg THC) per day and remained on that dose till the 
end of the study. The mean number of THC/CBD sprays was 9.26 and of THC 8.47 per day. 
Analysis of change from baseline in Numeral Rating Scale score was significantly in favour of 
THC/CBD extract, while THC extract showed non‐significant change. There was no change in 
dose of opioid background medication as well [98]. A long‐term, open‐label, follow‐up study 
investigated the long‐term tolerability of THC/CBD and THC oromucosal spray in 43 patients 
with terminal cancer‐related pain refractory to opioid who had participated in previously 
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mentioned trial. Patients self‐administered the medication to their optimal dose, again with 
limitation to a maximum of 48 sprays per day. The duration of treatment with THC/CBD spray 
(39 patients) was from minimum of 2 and maximum of 579 days (median 25 days) while treat‐
ment with THC spray lasted from 4 up to 657 days (median 151.5 days). THC/CBD spray was 
found to be well tolerated in long‐term use, and patients did not ask for higher dose of spray 
or other pain‐relieving medication. Long‐term use of cannabinoids did not result with loss 
of relieving effect on cancer pain [99]. Another randomised, placebo‐controlled, graded‐dose 
trial evaluating THC/CBD extract was conducted among opioid‐treated patients with poorly‐ 
controlled chronic pain who received placebo, low (1–4 sprays/day), medium (6–10 sprays/
day) or high dose (11–16 sprays/day) of 2.8 mg THC/2.5 mg CBD extract. During period of 
five weeks average pain, worst pain and sleep disruption were measured among 360 patients, 
of which 263 completed the study. Low and medium dose group of patients showed greater 
analgesia than placebo group and could be assumed as effective and safe, while in high‐dose 
group dose medication was not well‐tolerated and had no analgesic effect [100]. Another type 
of pain that usually occurs in cancer patients is chemotherapy‐induced peripheral neuropathy 
caused by neurotoxicity of drugs such as platinum compounds, vinca alkaloids, taxols and 
suramin. Although chemotherapy is limited to a short period of use and to a specific tissue, 
there is no adequate medications for prophylaxis of this type of neuropathy and therapy is 
restricted to symptomatic treatment of paraesthesia and pain. Ion  channel blockers and tri‐
cyclic anti‐depressants are first choice for treating neuropathy symptoms [101]. Being resis‐
tant to conventional treatments, neuropathy lowers life quality in affected patients and limits 
 dosing and duration of chemotherapy, which is crucial for extending their life. Preclinical 
studies implied that cannabinoid agonists can suppress neuropathy caused by chemothera‐
peutics, namely vincristine, paclitaxel and cisplatin; moreover, they had better efficacy than 
conventional treatment. For effectiveness estimation of cannabinoid extract for treating neu‐
ropathy, a randomised, placebo‐controlled, cross‐over pilot study with 18 patients was con‐
ducted. Patients were experiencing neuropathic pain, which persisted for three months after 
chemotherapy with paclitaxel, vincristine or cisplatin, and were treated with maximum of 12 
oromucosal sprays (each containing 2.7 mg THC and 2.5 mg CBD) per day. First study period 
lasted for four weeks with the result of five patients having a decrease of 2.6 on an 11‐point 
numeric rating scale for pain intensity, but in whole group, there was no significant difference 
between treated and placebo group. Ten patients have entered the extension phase for the next 
six months (five have completed the study), and confirmed pain  reduction by average dose of 
4.5 sprays per day. Despite inconsistent results, these findings support studying cannabinoids 
for chemotherapy‐induced  neuropathic pain in larger randomised controlled trials [102].
7.4. Cannabis and cancer associated anorexia/cachexia
Many cancer patients experience cachexia, anorexia as well as progressive loss of adipose tis‐
sue and skeletal muscle mass. Poor chemotherapy response and decreased survival are often 
connected with cachexia, a syndrome characterised by systemic inflammation, negative protein 
and energy balance, and an involuntary loss of body mass [103]. Majority of clinical studies 
dealing with cachexia and anorexia are focused on AIDS patients and as a result dronabinol 
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was approved for treatment of anorexia associated with weight loss in patients with AIDS. Still 
there are some clinical evidences that show that cannabinoids could be beneficial for patients 
with cancer‐associated anorexia/cachexia. One of earliest trials with cancer patients, in 1976, 
showed that oral THC in doses up to 15 mg per day stimulated appetite and produced signifi‐
cant weight gain [104]. Eighteen cancer patients with anorexia and life expectancy more than 4 
weeks underwent a phase II study of THC under regime 2.5 mg tree times per day, one hour 
after meal. Thirteen patients responded positively to the appetite stimulating effects of THC, but 
rather surprising was the fact that nausea was common side‐effect [105]. In contrast, study con‐
ducted in 2006 did not confirm these results. Multi‐centre, phase II, randomised, double blind, 
placebo controlled clinical trial included 164 patients with advanced incurable cancer and invol‐
untary weight loss more than 5%. Patients were divided in placebo, cannabis extract (2.5 mg 
THC and 1 mg CBD in a capsule) or THC (2.5 mg in a capsule) group, and they were assigned 
to take capsules twice per day, one hour before meal for six weeks. There were no significant 
differences between groups considering appetite, quality of life, cannabinoid related toxicity, 
mood and nausea [106]. It is rather unusual that in this large trial there were no side effects, 
which suggest that administrated dose of cannabinoids is suboptimal. Moreover, in case of the 
use of cannabinoids for anorexia and cachexia, European Palliative Care Research Collaborative 
noticed that dose‐regimen of THC used in clinical trials may be the reason for its lack of efficacy. 
They concluded that for future trials individual dose titration could be more efficient [107, 108]. 
These theses were confirmed in another randomised, double‐blind, placebo‐controlled pilot trial 
in which influence of THC on taste improvement, smell perception, appetite, caloric intake and 
quality of life was explored. Twenty‐one advanced cancer patients, with poor appetite and che‐
mosensory alterations, received THC (2.5 mg, twice per day) and had the option to increase their 
drug dose to a maximum of 20 mg/day. Though study population was not specifically cachexic, 
THC‐treated patients had improvement in taste, appetite, protein consumption and sleep qual‐
ity [109].
To summarise, cannabinoids show positive results in various clinical trials considering treat‐
ment of nausea, vomiting, pain and anorexia/cachexia while clinical anti‐cancer studies are 
yet to be reported. The perspective of cannabis‐based therapy also depends on a paradigm 
shift from illicit drug to clinically proved medicine. Due to their acceptable safety profile, with 
side effects that are generally tolerable and reversible [92], clinical trials testing them as single 
drugs or in combination therapies in various types of cancer are needed, particularly with 
respect to their effects on tumour growth and patient survival.
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